Core Viewpoint - Lantheus Holdings, Inc. is a significant player in the diagnostic medical imaging sector, facing legal challenges but showing resilience in stock performance and potential for growth [1][3][5]. Company Overview - Lantheus Holdings, Inc. specializes in developing and commercializing diagnostic medical imaging agents and products, operating within the healthcare sector [1]. - The company holds a substantial market position despite competition in the medical imaging industry [1]. Stock Performance - As of December 11, 2025, the stock price of LNTH was $63.09, with a price target set by Truist Financial at $80, indicating a potential increase of approximately 26.8% [2][6]. - The stock has fluctuated between $61.21 and $63.195 during the trading day, with a yearly high of $111.29 and a low of $47.25 [4]. - The market capitalization of Lantheus is approximately $4.32 billion, reflecting its significant presence in the market [4]. Legal Challenges - The company is currently under investigation by Grabar Law Office for potential breaches of fiduciary duties, which is part of a broader federal securities fraud class action complaint [2][3][6]. - Shareholders who purchased shares before November 6, 2024, may seek corporate reforms and financial restitution due to the ongoing legal scrutiny [3]. Investor Interest - The trading volume for LNTH on the NASDAQ exchange is 914,143 shares, indicating active investor interest despite the legal challenges [5]. - The stock has shown resilience with a recent increase of 3.73%, reaching $63.09 [3][6].